Positions

Overview

  • Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics. Dr. Curtis currently holds the William J. Koopman Endowed Professorship in Rheumatology and Immunology at UAB. He is the Co-Director of the UAB Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders, which has a major emphasis on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. Additionally, as the Director of the UAB Arthritis Clinical Intervention Program, he leads the clinical trials unit for the rheumatology division at UAB, with a particular focus on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large data sources to study comparative effectiveness questions across multiple chronic diseases. These data sources include national administrative data from Medicare and commercial health plans, electronic health record data, and large registries. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016. The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis’s research interests. He served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He is the Co-PI of the PCORI-funded Patient Powered Research Network “Arthritis-Power” registry, focused on RA, psoriasis, and psoriatic arthritis. He also leads the multi-center NIH-funded large pragmatic randomized controlled trial “VERVE” studying the safety and effectiveness of the live herpes zoster vaccine in patients receiving biologic agents. He is a member of the Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) Herpes Zoster workgroup. In 2015, he was appointed as a member to the FDA Arthritis Advisory Committee. Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures. Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), the American Medical Informatics Association (AMIA), and the American Society of Bone and Mineral Research (ASBMR). He has been on the editorial board for Arthritis & Rheumatism, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R). He has authored more than 350 peer-reviewed manuscripts, review articles and book chapters.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials.Arthritis Care and Research.  71:319-322. 2019
    2019 Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada.Annals of the Rheumatic Diseases.  78:e18. 2019
    2019 Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis.Clinical Rheumatology2019
    2019 Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.Journal of Rheumatology2019
    2019 Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.PLoS ONE.  14:e0210459. 2019
    2019 Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study.Arthritis Care and Research.  71:80-87. 2019
    2019 Risk of subsequent fracture after prior fracture among older women.Osteoporosis International.  30:79-92. 2019
    2018 Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.Chest.  154:1311-1320. 2018
    2018 Importance of Recent Fracture as Predictor of Imminent Fracture Risk.Current Osteoporosis Reports.  16:738-745. 2018
    2018 Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States.Journal of Rheumatology2018
    2018 Screening of Hyperlipidemia among Patients with Rheumatoid Arthritis in the United States.Arthritis Care and Research2018
    2018 Correction to: Hip fracture trends in the United States, 2002 to 2015.Osteoporosis International.  29:2583. 2018
    2018 Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?Arthritis Care and Research.  70:1694-1699. 2018
    2018 The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group.Arthritis Care and Research2018
    2018 Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate.Arthritis Care and Research2018
    2018 Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data.Arthritis Care and Research.  70:1541-1545. 2018
    2018 Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions.Journal of Bone and Mineral Research.  33:1881-1888. 2018
    2018 Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic Conditions.Medical Care.  56 Suppl 10 Suppl 1:S16-S21. 2018
    2018 Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study.Arthritis and Rheumatology.  70:1565-1571. 2018
    2018 Low Persistence Rates in Rheumatoid Arthritis Patients Treated with Triple Therapy are Attributed to Adverse Drug Events Associated with Sulfasalazine.Arthritis Care and Research2018
    2018 A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences.Advances in Therapy.  35:1333-1355. 2018
    2018 Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis.Quality of Life Research.  27:2443-2451. 2018
    2018 Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.Clinical Rheumatology.  37:2331-2340. 2018
    2018 Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores.Clinical Rheumatology2018
    2018 Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain.Journal of the American Medical Association.  320:508. 2018
    2018 An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches.The Permanente Journal.  22. 2018
    2018 Development of algorithms for identifying fatal cardiovascular disease in Medicare claims.Pharmacoepidemiology and Drug Safety.  27:740-750. 2018
    2018 Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.Annals of the Rheumatic Diseases.  77:1012-1016. 2018
    2018 Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.Drug Safety.  41:545-553. 2018
    2018 Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.Rheumatology and Therapy.  5:283-291. 2018
    2018 Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.Arthritis Research.  20:79. 2018
    2018 Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial.Journal of Bone and Mineral Research.  33:763-772. 2018
    2018 Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis.Arthritis Care and Research.  70:679-684. 2018
    2018 Reply.Arthritis and Rheumatology.  70:795-796. 2018
    2018 Defining and characterizing sustained remission in patients with rheumatoid arthritis.Clinical Rheumatology.  37:885-893. 2018
    2018 Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician Satisfaction.JCR: Journal of Clinical Rheumatology.  24:116-121. 2018
    2018 Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.Arthritis Research.  20:60. 2018
    2018 Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature.Clinical and Experimental Rheumatology.  36:263-274. 2018
    2018 Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.American Journal of Gastroenterology.  113:405-417. 2018
    2018 Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.Patient.  11:361-369. 2018
    2018 Advancing the Science and Practice of Medication Adherence.Journal of General Internal Medicine.  33:216-222. 2018
    2018 Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis.Gastroenterology.  154:748-750. 2018
    2018 Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) study.Archives of Osteoporosis.  13:4. 2018
    2018 Lipid management among individuals with inflammatory arthritis in the national REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.Journal of International Medical Research.  46:62-69. 2018
    2018 Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.PLoS ONE.  13:e0195123. 2018
    2018 Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis.Journal of Rheumatology.  45:40-44. 2018
    2017 Hip fracture trends in the United States, 2002 to 2015.Osteoporosis International.  29:717-722. 2017
    2017 Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study.Annals of the Rheumatic Diseases.  77:386-392. 2017
    2017 Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.Arthritis Research.  19:276. 2017
    2017 Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report.Journal of Rheumatology.  44:1894-1898. 2017
    2017 Reply.Arthritis and Rheumatology.  70:320. 2017
    2017 Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.Annals of the Rheumatic Diseases.  77:644-649. 2017
    2017 Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease Outcomes.Arthritis Care and Research.  69:1617-1619. 2017
    2017 Studies with herpes zoster vaccines in immune compromised patients.Expert Review of Vaccines.  16:1217-1230. 2017
    2017 Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study.Arthritis Research.  19:228. 2017
    2017 A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.Arthritis Research.  19:215. 2017
    2017 Stakeholders' views on data sharing in multicenter studies.Journal of Comparative Effectiveness Research.  6:537-547. 2017
    2017 Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.Arthritis and Rheumatology.  69:2351-2358. 2017
    2017 Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.Arthritis and Rheumatology.  69:1960-1968. 2017
    2017 Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.Seminars in Arthritis and Rheumatism.  47:472-477. 2017
    2017 Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.Clinical Therapeutics.  39:1680-1694.e2. 2017
    2017 Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.Clinical and Experimental Rheumatology.  35:614-622. 2017
    2017 Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Annals of the Rheumatic Diseases.  76:1253-1262. 2017
    2017 Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States.Arthritis and Rheumatology.  69:1733-1740. 2017
    2017 The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial.Osteoporosis International.  28:3061-3066. 2017
    2017 Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.Osteoporosis International.  28:2505. 2017
    2017 The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trial.Osteoporosis International.  28:3055-3060. 2017
    2017 Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.Osteoporosis International.  28:2495-2503. 2017
    2017 Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.Arthritis Research.  19:92. 2017
    2017 Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.Chest.  152:1120-1127. 2017
    2017 Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritisClinical and Experimental Rheumatology.  35:0390-0400. 2017
    2017 Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.Clinical and Experimental Rheumatology.  35:390-400. 2017
    2017 Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.Journal of Medical Economics (JME).  20:464-473. 2017
    2017 Improving medical record retrieval for validation studies in Medicare data.Pharmacoepidemiology and Drug Safety.  26:393-401. 2017
    2017 Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al.Arthritis and Rheumatology.  69:863-865. 2017
    2017 Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases.Journal of Rheumatology.  44:1083-1087. 2017
    2017 Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.BMC Cardiovascular Disorders.  17:76. 2017
    2017 Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising.Arthritis Research.  19:48. 2017
    2017 Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection.Journal of Rheumatology.  44:565-570. 2017
    2017 The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights.Pharmacoepidemiology and Drug Safety.  26:310-319. 2017
    2017 Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.Clinical Rheumatology.  36:683-688. 2017
    2017 Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases.Arthritis and Rheumatology.  69:439-446. 2017
    2017 Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.Arthritis Care and Research.  69:1845-1854. 2017
    2017 Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.JAMA Internal Medicine.  177:67-76. 2017
    2016 A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material.Contemporary Clinical Trials Communications.  4:14-24. 2016
    2016 Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.Arthritis Research.  18:280. 2016
    2016 Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.Lancet.  388:2763-2774. 2016
    2016 Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.Arthritis Care and Research.  69:1526-1534. 2016
    2016 Usability and Workflow Evaluation of "RhEumAtic Disease activitY" (READY). A Mobile Application for Rheumatology Patients and Providers.Applied Clinical Informatics.  7:1007-1024. 2016
    2016 Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review.Journal of Rheumatology.  43:1997-2009. 2016
    2016 Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.Arthritis Research.  18:241. 2016
    2016 Corrigendum to "Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases" Clin Ther 38 (2016) 1451-63.Clinical Therapeutics.  38:2506-2507. 2016
    2016 Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.Annals of the Rheumatic Diseases.  75:1813-1818. 2016
    2016 Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.Annals of the Rheumatic Diseases.  75:1843-1847. 2016
    2016 Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis.BMC Musculoskeletal Disorders.  17:405. 2016
    2016 The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.Arthritis Research.  18:210. 2016
    2016 Linkage of a Population-Based Cohort With Primary Data Collection to Medicare Claims: The Reasons for Geographic and Racial Differences in Stroke Study.American Journal of Epidemiology.  184:532-544. 2016
    2016 Knee Pain and Structural Damage as Risk Factors for Incident Widespread Pain: Data From the Multicenter Osteoarthritis Study.Arthritis Care and Research.  69:826-832. 2016
    2016 Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients.Pediatric Rheumatology.  14:49. 2016
    2016 A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study.Contemporary Clinical Trials Communications.  3:32-38. 2016
    2016 Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.Arthritis and Rheumatology.  69:46-57. 2016
    2016 Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.Controlled Clinical Trials.  50:106-115. 2016
    2016 Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis.BMC Cancer.  16:381. 2016
    2016 Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain.Arthritis and Rheumatology.  68:1669-1676. 2016
    2016 Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.Advances in Therapy.  33:1347-1359. 2016
    2016 Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.Osteoporosis International.  27:3239-3249. 2016
    2016 Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.Arthritis Care and Research.  69:313-322. 2016
    2016 Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry.Journal of Rheumatology.  43:1027-1029. 2016
    2016 Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.Rheumatology and Therapy.  3:103-115. 2016
    2016 Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.Clinical Therapeutics.  38:1451-1463. 2016
    2016 Reenergizing Research While Improving Patient Care.Provider.  42:37-passim. 2016
    2016 Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.Arthritis and Rheumatology.  68:2612-2617. 2016
    2016 Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.Arthritis and Rheumatology.  68:2403-2411. 2016
    2016 Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.Annals of the Rheumatic Diseases.  75:831-841. 2016
    2016 Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.Arthritis Research.  18:94. 2016
    2016 Association of Reduced eGFR and Albuminuria with Serious Fall Injuries among Older Adults.Clinical Journal of the American Society of Nephrology.  11:1236-1243. 2016
    2016 Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.Arthritis and Rheumatology.  68:2099-2105. 2016
    2016 Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.Arthritis and Rheumatology.  68:2328-2337. 2016
    2016 What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study.Journal of Bone and Mineral Research.  31:1500-1503. 2016
    2016 Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.Arthritis and Rheumatology.  68:577-586. 2016
    2016 Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis.Arthritis Care and Research.  68:1751-1757. 2016
    2016 Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration.Annals of the Rheumatic Diseases.  75:341-347. 2016
    2016 Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.JAMA Dermatology.  152:164-172. 2016
    2016 Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.Pharmacoepidemiology and Drug Safety.  25:827-835. 2016
    2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Arthritis and Rheumatology.  68:1-26. 2016
    2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Arthritis Care and Research.  68:1-25. 2016
    2016 Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.BMC Musculoskeletal Disorders.  17:231. 2016
    2016 Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability.PLoS ONE.  11:e0149781. 2016
    2016 Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Arthritis and Rheumatology.  68:56-66. 2016
    2016 Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting.The Permanente Journal.  20:4-10. 2016
    2016 Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: a randomized controlled trial.BMC Musculoskeletal Disorders.  17:369. 2016
    2016 Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009.The Permanente Journal.  20:4-12. 2016
    2016 Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents.J Psoriasis Psoriatic Arthritis.  1:128-137. 2016
    2016 Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.Arthritis and Rheumatology.  68:67-76. 2016
    2016 Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication.ClinicoEconomics and Outcomes Research.  8:707-715. 2016
    2015 A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.Arthritis and Rheumatology.  67:3104-3112. 2015
    2015 Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.Arthritis Care and Research.  67:1671-1678. 2015
    2015 The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis.Journal of Arthritis.  4. 2015
    2015 The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.British Journal of Clinical Pharmacology.  80:1447-1457. 2015
    2015 Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.Arthritis Research.  17:319. 2015
    2015 Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.Annals of the Rheumatic Diseases.  75:1757-1762. 2015
    2015 Bone Mineral Density as a Predictor of Subsequent Wrist Fractures: Findings From the Women's Health Initiative Study.Journal of Clinical Endocrinology and Metabolism.  100:4315-4324. 2015
    2015 Effectiveness and costs of biologics in veterans with rheumatoid arthritisThe American journal of pharmacy benefits.  7:280-289. 2015
    2015 Methotrexate Adherence Questionnaire: a New Tool to Assess Adherence in Patients Treated with Methotrexate.Value in Health.  18:A714-A715. 2015
    2015 Optimal use of available claims to identify a Medicare population free of coronary heart disease.American Journal of Epidemiology.  182:808-819. 2015
    2015 Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study.Journal of Bone and Mineral Research.  30:2086-2095. 2015
    2015 Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.Arthritis Care and Research.  67:1345-1353. 2015
    2015 Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans.BONE.  78:174-185. 2015
    2015 Mortality associated with medical therapy in ulcerative colitis.Annals of Internal Medicine.  163:I-28. 2015
    2015 An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users.Journal of Rheumatology.  42:1478-1483. 2015
    2015 Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.Arthritis Care and Research.  67:929-939. 2015
    2015 Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.Clinical Gastroenterology and Hepatology.  13:1293-1301.e5. 2015
    2015 Reply: To PMID 25201241.Arthritis Care and Research.  67:1041-1042. 2015
    2015 Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.Annals of the Rheumatic Diseases.  74:1150-1155. 2015
    2015 Disease activity in rheumatoid arthritis and the risk of cardiovascular events.Arthritis and Rheumatology.  67:1449-1455. 2015
    2015 Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Annals of the Rheumatic Diseases.  74:1065-1071. 2015
    2015 Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.Arthritis and Rheumatology.  67:1456-1464. 2015
    2015 Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.Arthritis Research.  17:136. 2015
    2015 Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study.Arthritis and Rheumatology.  67:1995-2003. 2015
    2015 Fractures and mortality in relation to different osteoporosis treatments.Clinical and Experimental Rheumatology.  33:302-309. 2015
    2015 Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.Arthritis Care and Research.  67:624-632. 2015
    2015 Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.Arthritis Care and Research.  67:731-736. 2015
    2015 Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.Journal of Managed Care && Speciality Pharmacy.  21:318-329. 2015
    2015 DXA Utilization Between 2006 and 2012 in Commercially Insured Younger Postmenopausal Women.Journal of Clinical Densitometry.  18:145-149. 2015
    2015 Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.Journal of Rheumatology.  42:504-512. 2015
    2015 Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases.Arthritis Care and Research.  67:313-325. 2015
    2015 An evaluation of clinical risk factors for estimating fracture risk in postmenopausal osteoporosis using an electronic medical record database.Osteoporosis International.  26:581-587. 2015
    2015 The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.Annals of the Rheumatic Diseases.  74:430-436. 2015
    2015 Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources.Seminars in Arthritis and Rheumatism.  44:381-388. 2015
    2015 Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.American Journal of Kidney Diseases.  65:249-258. 2015
    2015 Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).PLoS ONE.  10:e0135327. 2015
    2015 International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study.Osteoporosis International.  26:419-420. 2015
    2015 The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw.PLoS ONE.  10:e0131601. 2015
    2014 Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research.Arthritis Care and Research.  66:1790-1798. 2014
    2014 Republished: The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.Postgraduate Medical Journal.  90:722-729. 2014
    2014 Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.Annals of the Rheumatic Diseases.  73:1942-1948. 2014
    2014 The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine.Journal of Bone and Mineral Research.  29:2520-2526. 2014
    2014 Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.Arthritis Care and Research.  66:1604-1611. 2014
    2014 Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration.JCR: Journal of Clinical Rheumatology.  20:357-362. 2014
    2014 Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis.Journal of the European Academy of Dermatology and Venereology.  28:1380-1387. 2014
    2014 Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.Journal of Rheumatology.  41:1935-1943. 2014
    2014 Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.Journal of Rheumatology.  41:2078-2084. 2014
    2014 Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.Arthritis Research.  16:420. 2014
    2014 Effect of self-referral on bone mineral density testing and osteoporosis treatment.Medical Care.  52:743-750. 2014
    2014 Reply: To PMID 22504829.Arthritis Care and Research.  66:1271-1272. 2014
    2014 Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis.Journal of Medical Economics (JME).  17:555-566. 2014
    2014 Vaccinations for rheumatoid arthritis.Current Rheumatology Reports.  16:431. 2014
    2014 A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab.Annals of the Rheumatic Diseases.  73:1429-1430. 2014
    2014 Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.Clinical Therapeutics.  36:996-1004. 2014
    2014 Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.Arthritis Care and Research.  66:990-997. 2014
    2014 The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.Annals of the Rheumatic Diseases.  73:1301-1308. 2014
    2014 Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims.Circulation: Cardiovascular Quality and Outcomes.  7:611-619. 2014
    2014 Comparative effectiveness of infliximab and adalimumab for Crohn's disease.Clinical Gastroenterology and Hepatology.  12:811-817.e3. 2014
    2014 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.Journal of Rheumatology.  41:837-852. 2014
    2014 Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: a cross-sectional study.BMC Health Services Research.  14:195. 2014
    2014 "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients".BMC Musculoskeletal Disorders.  15:113. 2014
    2014 Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis.Annals of the Rheumatic Diseases.  73:785-786. 2014
    2014 Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.BMC Musculoskeletal Disorders.  15:112. 2014
    2014 Trends in the utilization and outcomes of Medicare patients hospitalized for hip fracture, 2000-2008.Journal of Aging and Health.  26:360-379. 2014
    2014 Death, debility, and destitution following hip fracture.Journals of Gerontology, Series A.  69:346-353. 2014
    2014 Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.Seminars in Arthritis and Rheumatism.  43:489-497. 2014
    2014 Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.Journal of Rheumatology.  41:216-226. 2014
    2014 Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial.Pharmacogenomics Journal.  14:48-53. 2014
    2014 High plasma levels of vitamin C and E are associated with incident radiographic knee osteoarthritis.Osteoarthritis and Cartilage.  22:190-196. 2014
    2014 Use of health plan combined with registry data to predict clinical trial recruitment.Clinical Trials.  11:96-101. 2014
    2014 Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.Journal of Bone and Mineral Research.  29:1-23. 2014
    2014 Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass.Osteoporosis International.  25:317-324. 2014
    2013 Commentary: measuring quality of care in osteoporosis.Current Osteoporosis Reports.  11:338-340. 2013
    2013 Commentary: the five Ws of a Fracture Liaison Service: why, who, what, where, and how? In osteoporosis, we reap what we sow.Current Osteoporosis Reports.  11:365-368. 2013
    2013 Epidemiologic research of invasive fungal infections using large healthcare databasesCurrent Fungal Infection Reports.  7:320-325. 2013
    2013 Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.Annals of the Rheumatic Diseases.  72:1813-1818. 2013
    2013 Identifying newly approved medications in Medicare claims data: a case study using tocilizumab.Pharmacoepidemiology and Drug Safety.  22:1214-1221. 2013
    2013 Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.Clinical Therapeutics.  35:1850-61.e1. 2013
    2013 Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.Arthritis Care and Research.  65:1743-1751. 2013
    2013 Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions.Arthritis Care and Research.  65:1719-1721. 2013
    2013 Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions.Arthritis Care and Research.  65:1719-1721. 2013
    2013 Using registries to identify adverse events in rheumatic diseases.Pediatrics.  132:e1384-e1394. 2013
    2013 Challenges in defining quality of care for glucocorticoid-induced osteoporosis: defending good against perfect.Journal of Rheumatology.  40:1640-1642. 2013
    2013 Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.Pharmacoepidemiology and Drug Safety.  22:1107-1114. 2013
    2013 Multimodal intervention to improve osteoporosis care in home health settings: results from a cluster randomized trial.Osteoporosis International.  24:2555-2560. 2013
    2013 Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes.Arthritis Care and Research.  65:1707-1712. 2013
    2013 Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients.Seminars in Arthritis and Rheumatism.  43:137-143. 2013
    2013 Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.American Journal of Medicine.  126:730.e9-730.e17. 2013
    2013 Reply: To PMID 22967869.American Journal of Ophthalmology.  156:408. 2013
    2013 Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.Arthritis and Rheumatism.  65:1985-1994. 2013
    2013 Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.Pharmacoepidemiology and Drug Safety.  22:842-849. 2013
    2013 Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009.Journal of Rheumatology.  40:1218-1225. 2013
    2013 Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases.Arthritis Care and Research.  65:1085-1094. 2013
    2013 Osteoporosis medication adherence: physician perceptions vs. patients' utilization.BONE.  55:1-6. 2013
    2013 Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.Arthritis and Rheumatism.  65:1430-1438. 2013
    2013 Low hemoglobin levels and recurrent falls in U.S. men and women: prospective findings from the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.American Journal of the Medical Sciences.  345:446-454. 2013
    2013 Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.Arthritis and Rheumatism.  65:1384-1389. 2013
    2013 Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.Journal of Rheumatology.  40:572-578. 2013
    2013 Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).Clinical and Experimental Rheumatology.  31:358-364. 2013
    2013 New methods for determining comparative effectiveness in rheumatoid arthritis.Current Opinion in Rheumatology.  25:325-333. 2013
    2013 Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis.Current Opinion in Rheumatology.  25:384-390. 2013
    2013 A close examination of healthcare expenditures related to fractures.Journal of Bone and Mineral Research.  28:816-820. 2013
    2013 Association between anti-TNF-α therapy and interstitial lung disease.Pharmacoepidemiology and Drug Safety.  22:394-402. 2013
    2013 Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study.Osteoporosis International.  24:1185-1193. 2013
    2013 Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data.Arthritis Research.  15:404. 2013
    2013 Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.Journal of the American Medical Association.  309:887-895. 2013
    2013 Magnitude and consequences of misclassification of incident hip fractures in large cohort studies: the Study of Osteoporotic Fractures and Medicare claims data.Osteoporosis International.  24:801-810. 2013
    2013 Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis.Journal of Rheumatology.  40:127-136. 2013
    2013 Physicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System.Arthritis Care and Research.  65:235-243. 2013
    2013 Development of a multi-biomarker disease activity test for rheumatoid arthritis.PLoS ONE.  8:e60635. 2013
    2013 Generic alendronate use among Medicare beneficiaries: are Part D data complete?Pharmacoepidemiology and Drug Safety.  22:55-63. 2013
    2013 Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.American Journal of Ophthalmology.  155:183-189.e1. 2013
    2013 Mycobacterial diseases and antitumour necrosis factor therapy in USA.Annals of the Rheumatic Diseases.  72:37-42. 2013
    2013 The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health.Controlled Clinical Trials.  34:90-100. 2013
    2013 Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.Arthritis and Rheumatism.  65:48-58. 2013
    2013 Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: feasibility, satisfaction, and sample size.Patient Preference and Adherence.  7:517-523. 2013
    2012 A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women.Journal of Bone and Mineral Research.  27:2603-2610. 2012
    2012 Association between anti-TNF-α therapy and all-cause mortality.Pharmacoepidemiology and Drug Safety.  21:1311-1320. 2012
    2012 Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.Arthritis Care and Research.  64:1855-1863. 2012
    2012 Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.Arthritis Care and Research.  64:1819-1828. 2012
    2012 Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.Arthritis Care and Research.  64:1804-1810. 2012
    2012 Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity.Arthritis Care and Research.  64:1794-1803. 2012
    2012 Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.Controlled Clinical Trials.  33:1211-1216. 2012
    2012 Recent trends in hip fracture rates by race/ethnicity among older US adults.Journal of Bone and Mineral Research.  27:2325-2332. 2012
    2012 Postherpetic neuralgia after herpes zoster vaccination.Journal of the American Medical Association.  308:1427. 2012
    2012 Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.Arthritis Care and Research.  64:1480-1489. 2012
    2012 A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.Arthritis and Rheumatism.  64:2824-2835. 2012
    2012 Defining physiologically "normal" vitamin D in African Americans.Osteoporosis International.  23:2283-2291. 2012
    2012 Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.Arthritis Care and Research.  64:1282-1291. 2012
    2012 Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:2773-2780. 2012
    2012 Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.Journal of the American Medical Association.  308:43-49. 2012
    2012 Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.Arthritis Care and Research.  64:1054-1060. 2012
    2012 Management of osteoporosis among the elderly with other chronic medical conditions.Drugs and Aging.  29:549-564. 2012
    2012 Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.Journal of Rheumatology.  39:1326-1333. 2012
    2012 Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study.Journal of Clinical Endocrinology and Metabolism.  97:1937-1944. 2012
    2012 Malignancy validation in a United States registry of rheumatoid arthritis patients.BMC Musculoskeletal Disorders.  13:85. 2012
    2012 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care and Research.  64:625-639. 2012
    2012 Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?Pharmacoepidemiology and Drug Safety.  21:524-534. 2012
    2012 Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.Applied Health Economics and Health Policy.  10:163-173. 2012
    2012 Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.Arthritis Care and Research.  64:658-667. 2012
    2012 Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes.Journal of Bone and Mineral Research.  27:858-864. 2012
    2012 Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.Arthritis Care and Research.  64:612-615. 2012
    2012 Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan.BONE.  50:870-875. 2012
    2012 Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:1263-1271. 2012
    2012 Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.Clinical Therapeutics.  34:788-802.e3. 2012
    2012 Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations.Arthritis and Rheumatism.  64:630-638. 2012
    2012 Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.Annals of the Rheumatic Diseases.  71:198-205. 2012
    2012 In responseEmerging Infectious Diseases.  18:361. 2012
    2012 Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial.Annals of the Rheumatic Diseases.  71:206-212. 2012
    2012 Evaluating comorbidity scores based on health service expenditures.Medicare & medicaid research review.  2. 2012
    2012 Improving osteoporosis care in high-risk home health patients through a high-intensity intervention.Controlled Clinical Trials.  33:206-212. 2012
    2012 ReplyArthritis Care and Research.  64:157-158. 2012
    2012 Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.Journal of Clinical Densitometry.  15:92-102. 2012
    2011 Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.Journal of the American Medical Association.  306:2331-2339. 2011
    2011 Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.Arthritis Care and Research.  63:1680-1690. 2011
    2011 Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.Rheumatology.  50:2223-2232. 2011
    2011 Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.Arthritis Care and Research.  63:1672-1679. 2011
    2011 Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.Pharmacoepidemiology and Drug Safety.  20:1199-1209. 2011
    2011 Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients.Pharmacoepidemiology and Drug Safety.  20:1150-1158. 2011
    2011 Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.Arthritis Care and Research.  63:1415-1424. 2011
    2011 Geographic distribution of endemic fungal infections among older persons, United States.Emerging Infectious Diseases.  17:1664-1669. 2011
    2011 Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.Journal of Rheumatology.  38:1745-1750. 2011
    2011 Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.Arthritis and Rheumatism.  63:2203-2208. 2011
    2011 Erratum: Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (Journal of Bone and Mineral Research (2010) 25 (2267-2294))Journal of Bone and Mineral Research.  26:1987. 2011
    2011 Improving osteoporosis care through multimodal interventions: insights from the University of Alabama at Birmingham Center for Education and Research on Therapeutics.Osteoporosis International.  22 Suppl 3:445-450. 2011
    2011 The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.Annals of the Rheumatic Diseases.  70:1401-1406. 2011
    2011 Consistency of knee pain and risk of knee replacement: the Multicenter Osteoarthritis Study.Journal of Rheumatology.  38:1390-1395. 2011
    2011 Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.Journal of Clinical Densitometry.  14:240-262. 2011
    2011 Corrigendum to "Cost burden of second fracture in the US Health System" [Bone 48 (2011) 828-836]BONE.  48:1429. 2011
    2011 Medical costs of osteoporosis in the elderly Medicare population.Osteoporosis International.  22:1835-1844. 2011
    2011 Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.Journal of Rheumatology.  38:990-996. 2011
    2011 Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.Clinical Therapeutics.  33:679-707. 2011
    2011 High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.Annals of the Rheumatic Diseases.  70:785-791. 2011
    2011 Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials.Medical Care.  49:427-435. 2011
    2011 Response to Letter to Editor on validation study identifying bacterial infections in rheumatoid arthritis patientsJournal of Clinical Epidemiology.  64:573. 2011
    2011 Clinical and demographic factors associated with fractures among older Americans.Osteoporosis International.  22:1263-1274. 2011
    2011 Cost burden of second fracture in the US health system.BONE.  48:828-836. 2011
    2011 Erratum: Clinical and demographic factors associated with fractures among older Americans (Osteoporosis International DOI: 10.1007/s00198-010-1300-8)Osteoporosis International.  22:1275-1276. 2011
    2011 The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.Journal of Bone and Mineral Research.  26:683-688. 2011
    2011 Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.Annals of the Rheumatic Diseases.  70:576-582. 2011
    2011 TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis.Medicine.  90:139-145. 2011
    2011 The incidence of gastrointestinal perforations among rheumatoid arthritis patients.Arthritis and Rheumatism.  63:346-351. 2011
    2011 Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.Arthritis Research.  13:R155. 2011
    2011 Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics.Current Medical Research and Opinion.  27:71-78. 2011
    2011 The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.Arthritis Research.  13:R174. 2011
    2011 Which fractures are most attributable to osteoporosis?Journal of Clinical Epidemiology.  64:46-53. 2011
    2010 Predicting hip and major osteoporotic fractures using administrative data.Archives of Internal Medicine -New Series-.  170:1940-1942. 2010
    2010 American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Care and Research.  62:1515-1526. 2010
    2010 Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.Journal of Bone and Mineral Research.  25:2267-2294. 2010
    2010 Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity.Annals of the Rheumatic Diseases.  69:1920-1925. 2010
    2010 Consistency of knee pain: correlates and association with function.Osteoarthritis and Cartilage.  18:1250-1255. 2010
    2010 Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients.Arthritis Care and Research.  62:1481-1488. 2010
    2010 Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death.Journal of the American Medical Directors Association.  11:584-591. 2010
    2010 Osteoporosis care in the United States after declines in reimbursements for DXA.Journal of Clinical Densitometry.  13:352-360. 2010
    2010 Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.Osteoporosis International.  21:1573-1584. 2010
    2010 Health services utilization after fractures: evidence from Medicare.Journals of Gerontology, Series A.  65:1012-1020. 2010
    2010 Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.Annals of the Rheumatic Diseases.  69:1612-1617. 2010
    2010 A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.Seminars in Arthritis and Rheumatism.  40:2-14.e1. 2010
    2010 Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines.Journal of Bone and Mineral Research.  25:1506-1511. 2010
    2010 Identifying types of nursing facility stays using medicare claims data: An algorithm and validationHealth Services and Outcomes Research Methodology.  10:100-110. 2010
    2010 Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics.Medical Care.  48:S83-S89. 2010
    2010 Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report.Special Care in Dentistry.  30:77-82. 2010
    2010 Pre-radiographic MRI findings are associated with onset of knee symptoms: the most study.Osteoarthritis and Cartilage.  18:323-328. 2010
    2010 Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis.Journal of Rheumatology.  37:275-281. 2010
    2010 Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity.Arthritis Care and Research.  62:101-107. 2010
    2010 Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.Annals of the Rheumatic Diseases.  69:43-47. 2010
    2010 High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: the MOST study.Annals of the Rheumatic Diseases.  69:163-168. 2010
    2010 The delivery of evidence-based preventive care for older Americans with arthritis.Arthritis Research.  12:R144. 2010
    2009 Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005.Journal of Bone and Mineral Research.  24:2050-2055. 2009
    2009 "Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures?Osteoporosis International.  20:1969-1972. 2009
    2009 Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation research.Osteoporosis International.  20:1921-1927. 2009
    2009 Skeletal health among African Americans with recent-onset rheumatoid arthritis.Arthritis and Rheumatism.  61:1379-1386. 2009
    2009 Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms.Seminars in Arthritis and Rheumatism.  39:132-143. 2009
    2009 Validity of physician-reported hospitalized infections in a US arthritis registry.Rheumatology.  48:1269-1272. 2009
    2009 Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data.Osteoporosis International.  20:1507-1515. 2009
    2009 The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States.Osteoporosis International.  20:1553-1561. 2009
    2009 Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender.Journal of General Internal Medicine.  24:956-962. 2009
    2009 Adherence to osteoporosis treatments: room for improvement.Current Opinion in Rheumatology.  21:356-362. 2009
    2009 RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.Osteoporosis International.  20:973-978. 2009
    2009 Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study.Osteoporosis International.  20:819-826. 2009
    2009 Management of osteoporosis among home health and long-term care patients with a prior fracture.Southern Medical Journal.  102:397-404. 2009
    2009 Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.Journal of Clinical Epidemiology.  62:321-327.e7. 2009
    2009 Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.Medical Care.  47:334-341. 2009
    2009 Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job?Current Osteoporosis Reports.  7:27-34. 2009
    2009 Bridging the osteoporosis quality chasm.Journal of Bone and Mineral Research.  24:3-7. 2009
    2009 Identification and validation of vertebral compression fractures using administrative claims data.Medical Care.  47:69-72. 2009
    2008 Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.Osteoporosis International.  19:1613-1620. 2008
    2008 Muscle mass is more strongly related to hip bone mineral density than is quadriceps strength or lower activity level in adults over age 50 year.Journal of Clinical Densitometry.  11:503-510. 2008
    2008 Regional variation in the denial of reimbursement for bone mineral density testing among US Medicare beneficiaries.Journal of Clinical Densitometry.  11:568-574. 2008
    2008 Tumor necrosis factor inhibitors and infection complications.Current Rheumatology Reports.  10:383-389. 2008
    2008 Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example.Medical Care.  46:969-975. 2008
    2008 Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users.Journal of Bone and Mineral Research.  23:1435-1441. 2008
    2008 Mortality and osteoporotic fractures: Is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26. 2008
    2008 Mortality and osteoporotic fractures: is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26:S125-S137. 2008
    2008 Longitudinal trends in use of bone mass measurement among older americans, 1999-2005.Journal of Bone and Mineral Research.  23:1061-1067. 2008
    2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Arthritis and Rheumatism.  59:762-784. 2008
    2008 Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.Current Opinion in Rheumatology.  20:320-326. 2008
    2008 Biologics and heart failure in rheumatoid arthritis: are we any wiser?Current Opinion in Rheumatology.  20:327-333. 2008
    2008 Improving quality of care in osteoporosis: opportunities and challenges.Current Rheumatology Reports.  10:123-130. 2008
    2008 The epidemiology of glucocorticoid-associated adverse events.Current Opinion in Rheumatology.  20:131-137. 2008
    2008 Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugs.Arthritis and Rheumatism.  59:227-233. 2008
    2008 Leg-length inequality is not associated with greater trochanteric pain syndrome.Arthritis Research.  10:R62. 2008
    2007 Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behavior.Arthritis and Rheumatism.  57:1539-1545. 2007
    2007 Challenges in defining and improving osteoporosis quality of careClinical and Experimental Rheumatology.  25. 2007
    2007 Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.Arthritis and Rheumatism.  56:4226-4227. 2007
    2007 Challenges in defining and improving osteoporosis quality of care.Clinical and Experimental Rheumatology.  25:142-146. 2007
    2007 Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.Rheumatology.  46:1688-1693. 2007
    2007 Randomized trial to improve fracture prevention in nursing home residents.American Journal of Medicine.  120:886-892. 2007
    2007 Greater trochanteric pain syndrome: epidemiology and associated factors.Archives of Physical Medicine and Rehabilitation.  88:988-992. 2007
    2007 Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture.Osteoporosis International.  18:553-559. 2007
    2007 Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.Arthritis and Rheumatism.  56:1125-1133. 2007
    2007 Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial.Archives of Internal Medicine -New Series-.  167:591-596. 2007
    2007 Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.Arthritis and Rheumatism.  57:343-346. 2007
    2007 Prevention and treatment of glucocorticoid-induced osteoporosis.Current Osteoporosis Reports.  5:14-21. 2007
    2006 Osteoporosis in the home health care setting: A window of opportunity?Arthritis and Rheumatism.  55:971-975. 2006
    2006 Treatment of rheumatoid arthritis.American Journal of Health-System Pharmacy.  63:2451-2465. 2006
    2006 Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.Pharmacoepidemiology and Drug Safety.  15:710-718. 2006
    2006 Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.American Journal of Health-System Pharmacy.  63:1837-1851. 2006
    2006 Trends in prevention of glucocorticoid-induced osteoporosis.Journal of Rheumatology.  33:1651-1657. 2006
    2006 Population-based assessment of adverse events associated with long-term glucocorticoid use.Arthritis and Rheumatism.  55:420-426. 2006
    2006 Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system.Journal of Rheumatology.  33:562-566. 2006
    2006 Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy.AIDS Research and Human Retroviruses.  22:125-131. 2006
    2006 Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.Osteoporosis International.  17:1268-1274. 2006
    2006 Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions.Pharmacoepidemiology and Drug Safety.  15:11-18. 2006
    2005 A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs.American Journal of Managed Care.  11:537-543. 2005
    2005 Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.Arthritis and Rheumatism.  52:2485-2494. 2005
    2005 Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data.Journal of the National Medical Association.  97:1155-1160. 2005
    2004 Swallowing difficulties from "DISH-phagia".Journal of Rheumatology.  31:2526-2527. 2004
    2004 Evaluating and improving the quality of care in rheumatic disease.Expert Review of Pharmacoeconomics and Outcomes Research.  4:429-439. 2004
    2004 Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study.Arthritis and Rheumatism.  50:72-77. 2004
    2003 Nonsteroidal antiinflammatory drug toxicity monitoring and safety practices.Journal of Rheumatology.  30:2680-2688. 2003
    2003 The Use of Glucocorticoids in Arthritis – 20 Clinical PearlsJournal of Musculoskeletal Medicine.  20:425-433. 2003
    2000 Reply.Indian Journal of Psychiatry.  42:107-108. 2000

    Chapter

    Year Title Altmetric
    2018 Studies of Biologicals 2018
    2009 Bisphosphonate Therapy for Osteoporosis 2009
    2008 Glucocorticoid-Induced Osteoporosis.  1135-1166. 2008
    2005 Prevention and Treatment 2005
    2004 Therapeutic Dictionary of Rheumatology and Immunology 2004
    2001 Glucocorticoid-induced osteoporosis.  140-145. 2001
    2000 New Biologics: Cytokines 2000

    Research Overview

  • Rheumatoid Arthritis
    Psoriatic Arthritis
    Ankylosing Spondylitis
    Osteoporosis
  • Principal Investigator On

  • Private Grant  awarded by AMGEN, INC. 2011 - 2024
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2016 - 2021
  • Harnessing PCORnet to Study Comparative Effectiveness and Safety of Biologic Therapies  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE 2016 - 2020
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC. 2018 - 2020
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC. 2018 - 2020
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2019
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC. 2015 - 2019
  • Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2014 - 2019
  • Arthritis Patient Partnership with Comparative Effectiveness Researchers (Arthritis Patient PoWER)  awarded by GLOBAL HEALTHY LIVING FOUNDATION 2015 - 2019
  • UAB Multidisciplinary Clinical Research Center - Project 2: Facilitating Treat-to-Target Using Novel Health Technology with Decision Support  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • Treatments Against RA and Effect of FDG PET-CT: The TARGET Trial  awarded by Brigham and Women's Hospital 2015 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2019
  • Private Grant  awarded by RADIUS HEALTH 2018 - 2019
  • Private Grant  awarded by AMGEN, INC. 2015 - 2019
  • Private Grant  awarded by Genentech 2014 - 2019
  • Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-Management  awarded by University of North Carolina at Chapel Hill 2016 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2014 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2018
  • Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis  awarded by Oregon Health & Science University 2016 - 2018
  • Privacy-Preserving Analytic and Data-Sharing Methods for Clinical and Patient-Powered Research Data Research Networks  awarded by HARVARD PILGRIM HEALTH CARE 2015 - 2017
  • Private Grant  awarded by Pfizer Pharmaceuticals 2009 - 2017
  • Centers of Research Translation (CoRT) - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Private Grant  awarded by CELGENE CORPORATION 2010 - 2017
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014 - 2017
  • Making PROMISE Meaningful to Patients and Providers in Clinical Practice  awarded by Johns Hopkins University 2015 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2013 - 2016
  • Patient Valued Comparative Effectiveness of Corticosteroids Versus Anti-TNF Alpha Therapy for Inflammatory Bowel Disease  awarded by University of Pennsylvania 2013 - 2016
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2016
  • Private Grant  awarded by AMGEN, INC. 2014 - 2016
  • A Pilot Study of the Safety and Effectiveness of the Live Zoster Vaccine in Anti-TNF Users  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2013 - 2016
  • Private Grant  awarded by CONSORTIUM OF RHEUMATOLOGY RESEARCHERS OF NORTH AMERICA, INC. 2008 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2014 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2012 - 2016
  • Private Grant  awarded by AMGEN, INC. 2014 - 2015
  • Private Grant  awarded by AMGEN, INC. 2012 - 2015
  • Private Grant  awarded by KNOLL PHARMACEUTICAL COMPANY 2007 - 2015
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2012 - 2015
  • Arthritis Patient Partnership With Comparative Effectiveness Researchers (AR-Power PPRN)  awarded by GLOBAL HEALTHY LIVING FOUNDATION 2014 - 2015
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2014 - 2015
  • Private Grant  awarded by UCB, INC. 2012 - 2015
  • Private Grant  awarded by Sanofi US Services Inc 2013 - 2015
  • Private Grant  awarded by Pfizer Pharmaceuticals 2013 - 2015
  • Private Grant  awarded by UCB, INC. 2012 - 2014
  • Longitudinal Comparative Effectiveness & Safety of Biologics in Autoimmunity  awarded by Agency for Healthcare Research and Quality/DHHS 2009 - 2014
  • Private Grant  awarded by Genentech 2012 - 2014
  • Private Grant  awarded by AMGEN, INC. 2014
  • Private Grant  awarded by Genentech 2007 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2010 - 2014
  • Private Grant  awarded by INCYTE CORPORATION 2009 - 2014
  • Private Grant  awarded by ELI LILLY AND COMPANY 2011 - 2014
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2012 - 2014
  • Private Grant  awarded by Genentech 2011 - 2013
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2011 - 2013
  • Private Grant  awarded by Genentech 2011 - 2013
  • Private Grant  awarded by ACTURIAL RESEARCH CORPORATION 2013
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2013
  • Private Grant  awarded by ANOLINX, LLC 2011 - 2013
  • Private Grant  awarded by CONSORTIUM OF RHEUMATOLOGY RESEARCHERS OF NORTH AMERICA, INC. 2007 - 2013
  • Private Grant  awarded by Genentech 2012 - 2013
  • ACE Protocol #ARA06  awarded by Duke University 2009 - 2013
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2007 - 2013
  • Private Grant  awarded by ELI LILLY AND COMPANY 2008 - 2013
  • Private Grant  awarded by UCB PHARMA, INC. 2011 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2010 - 2013
  • Private Grant  awarded by Genentech 2011 - 2013
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2008 - 2013
  • Private Grant  awarded by Centocor 2007 - 2013
  • Private Grant  awarded by UCB PHARMA, INC. 2011 - 2012
  • Coronary Heart Disease in Rheumatoid Arthritis  awarded by Arthritis Foundation 2011 - 2012
  • The TAKEOFF Trial: Clinical Trial Planning Grant  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2011 - 2012
  • Ethnic Differences in the Risk of Fracture and Vascular Disease  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2007 - 2012
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2007 - 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2009 - 2012
  • Safety and Effectiveness of Herpes Zoster Vaccination in Rheumatoid Arthritis Patients  awarded by American College of Rheumatology 2011 - 2012
  • Private Grant  awarded by Genentech 2008 - 2012
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2010 - 2012
  • Private Grant  awarded by Genentech 2009 - 2012
  • Long Term Risks and Extra-Skeletal Benefits of Biologics  awarded by Duke (Doris) Charitable Foundation 2007 - 2012
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2011
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2011
  • Private Grant  awarded by AMGEN, INC. 2007 - 2011
  • Kaiser Permanente Autoimmune Disease Registry  awarded by Kaiser Permanente 2009 - 2011
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2009 - 2011
  • Private Grant  awarded by UCB PHARMA, INC. 2008 - 2011
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2007 - 2011
  • Private Grant  awarded by ABBOTT LABORATORIES 2007 - 2011
  • Private Grant  awarded by WYETH PHARMACEUTICALS, INC. 2008 - 2011
  • ACE - Switching Anti-TNF-a Agents in Patients with RA with an Inadequate Response to TNF-a Inhibition - ACE  awarded by Duke University 2009 - 2011
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC. 2009 - 2010
  • Arthritis Foundation Investigator Award: Osteoporosis and Associated Stroke and MI in a Multi-Ethnic Cohort  awarded by Arthritis Foundation 2007 - 2010
  • Private Grant  awarded by AMGEN, INC. 2009 - 2010
  • Private Grant  awarded by Genentech 2007 - 2010
  • Investigator On

  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • Strengthening Translational Research in Diverse Enrollment (STRIDE)  awarded by UNIVERSITY OF MASSACHUSETTS (WORCESTER) 2016 - 2021
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Promo/Dissemination Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Tech Developments Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Rehabilitation Research Resource to Enhance Clinical Trials (REACT)  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • UAB Multidisciplinary Clinical Research Center (P60)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • ACE Protocol ARA08: Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA)  awarded by University of California, San Francisco 2015 - 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2016 - 2019
  • Outliers - Extreme Long-term Survivors with Metastatic Breast Cancer  awarded by University of Wisconsin-Madison 2018
  • The Relationship of Disease Activity to Medication use in the RISE Registry  awarded by American College of Rheumatology 2017 - 2018
  • Brain Thermometry: A Non-Invasive Method for Detecting Neuroinflammation in RA  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2016 - 2017
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • UAB Deep South Arthritis and Musculoskeletal CERTs  awarded by Agency for Healthcare Research and Quality/DHHS 2011 - 2017
  • Private Grant  awarded by Janssen 2016 - 2017
  • Private Grant  awarded by ABBVIE INC 2016
  • Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2016
  • Private Grant  awarded by AMGEN, INC. 2014 - 2015
  • Private Grant  awarded by AMGEN, INC. 2014 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015
  • Burden of Osteoporosis and Low Bone Density in the United States  awarded by National Osteoporosis Foundation 2012 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • Private Grant  awarded by AMGEN, INC. 2013 - 2014
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2012 - 2013
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2011 - 2013
  • Does Aggressive Treatment in Early RA Reduce Biomarkers of Cardiovascular Risk?  awarded by University of California, Los Angeles 2010 - 2013
  • Private Grant  awarded by AMGEN, INC. 2012 - 2013
  • Deep South Musculoskeletal Certs (DSMC)  awarded by Agency for Healthcare Research and Quality/DHHS 2007 - 2012
  • Private Grant  awarded by AMGEN, INC. 2010 - 2012
  • Education And Training

  • Doctor of Medicine, Oregon Health Sciences University
  • Master of Public Health, Oregon Health Sciences University
  • Oregon Health Science University Hospital & Clinic, Internship 2000
  • Oregon Health Science University Hospital & Clinic, Residency 2002
  • UAB Hospital, Postdoctoral Fellowship 2005
  • Full Name

  • Jeffrey Curtis
  • Blazerid

  • jcurtis